Infusional 5-FU for advanced colorectal cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• 5-Fluorouracil (5-FU) is a cornerstone chemotherapy agent.
• Bolus versus infusional administration schedules have been extensively studied.
• Optimizing 5-FU delivery is crucial for improving patient outcomes in various cancers.

Purpose of the Study:

• To compare the efficacy and toxicity of infusional versus bolus 5-Fluorouracil (5-FU) schedules.
• To evaluate the role of biochemical and temporal modulation in 5-FU therapy.
• To propose future trial designs for optimizing infusional 5-FU in advanced and adjuvant settings.

Main Methods:

• Review of five prospective randomized trials comparing bolus and infusional 5-FU schedules.
• Analysis of data on response rates, time to progression, and overall survival.
• Examination of toxicity profiles associated with different modulation strategies.

Main Results:

• Infusional 5-FU schedules demonstrate superior response rates, time to progression, and 2-year survival compared to bolus administration.
• Biochemical modulation (leucovorin, interferon) of infusional 5-FU does not enhance therapeutic effects but increases toxicity.
• Time-modulated (chronomodulation) infusional 5-FU shows potential for improved response rates and survival.

Conclusions:

• Infusional 5-FU is superior to bolus administration for colon cancer and should be the preferred method.
• Bolus 5-FU as a single agent for colon cancer should be abandoned.
• Further research is warranted to determine optimal infusion duration, dose intensity, and chronomodulation strategies for infusional 5-FU.